HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Result:
Patients with a HER2-positive breast cancer benefited from paclitaxel,
regardless of estrogen-receptor status, but paclitaxel did not benefit patients
with HER2-negative, estrogen-receptor–positive cancers.
I am HER2-negative, estrogen-receptor–positive..
The only difference in the test cases are that I am getting Dose Dense ( instead of traditional. every 3 weeks ).
I have 1 month to research on this to see whether I still want to continue with Taxol after my AC finishes.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment